Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beauty Farm Medical and Health Industry Inc. (2373.HK)
Shanghai, CN
Beauty Farm Medical and Health Industry Inc., established in 1993 and based in Shanghai, People's Republic of China, delivers comprehensive beauty and health management services across China. Its diverse offerings encompass traditional beauty treatments; advanced aesthetic medical services, including non-surgical options like energy-based therapies and injections, as well as surgical procedures; and specialized subhealth assessment and intervention programs. As of June 30, 2022, the company operated a network of 352 stores under its BeautyFarm, Palaispa, Neology, and CellCare brands, with 177 being directly owned and 175 franchised.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.17% | -0.81% | -4.64% | -25.85% | -22.50% | -28.20% | +6.14% | -7.00% | -34.13% | -34.13% | -34.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+16.7% ★ Q4'25: +39.1% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%+38.4% ★ Q4'25: +53.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+19.3% ★ Q4'25: +37.0% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+15.1% ★ Q4'25: +15.5% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%— Q4'25: -337.1% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%+0.9% Q4'25: +0.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.15× ★ Q4'25: 1.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.64B
est: 1.81B (-9.8%)
|
2.15B
est: 2.09B (+2.7%)
|
2.57B
est: 2.59B (-0.9%)
|
3.00B
est: 3.05B (-1.5%)
|
4.14B
4.05B – 4.19B
+35.9% YoY
|
4.67B
4.49B – 4.74B
+12.8% YoY
|
5.18B
5.02B – 5.25B
+10.8% YoY
|
| EBITDA |
452.43M
est: 496.80M (-8.9%)
|
644.82M
est: 524.77M (+22.9%)
|
427.49M
est: 651.68M (-34.4%)
|
603.50M
est: 765.32M (-21.1%)
|
1.04B
1.02B – 1.05B
+35.9% YoY
|
1.17B
1.13B – 1.19B
+12.8% YoY
|
1.30B
1.26B – 1.32B
+10.8% YoY
|
| EBIT |
155.19M
est: 239.68M (-35.3%)
|
313.08M
est: 279.46M (+12.0%)
|
310.14M
est: 347.04M (-10.6%)
|
451.78M
est: 407.56M (+10.9%)
|
553.86M
542.23M – 560.67M
+35.9% YoY
|
624.58M
600.61M – 634.14M
+12.8% YoY
|
692.30M
671.39M – 701.91M
+10.8% YoY
|
| Net Income |
103.11M
est: 117.08M (-11.9%)
|
215.66M
est: 203.94M (+5.7%)
|
228.46M
est: 236.97M (-3.6%)
|
317.56M
est: 322.19M (-1.4%)
|
431.42M
421.15M – 441.70M
+33.9% YoY
|
529.54M
495.97M – 563.11M
+22.7% YoY
|
624.18M
610.90M – 637.46M
+17.9% YoY
|
| SGA |
171.12M
est: 244.56M (-30.0%)
|
166.85M
est: 387.36M (-56.9%)
|
849.84M
est: 481.03M (+76.7%)
|
992.71M
est: 564.92M (+75.7%)
|
767.71M
751.59M – 777.15M
+35.9% YoY
|
865.74M
832.51M – 878.98M
+12.8% YoY
|
959.59M
930.62M – 972.92M
+10.8% YoY
|
| EPS |
0.45
est: 0.49 (-8.0%)
|
0.94
est: 0.89 (+5.9%)
|
0.99
est: 1.03 (-4.2%)
|
1.38
est: 1.39 (-0.5%)
|
1.86
1.82 – 1.90
+34.2% YoY
|
2.28
2.14 – 2.43
+22.7% YoY
|
2.69
2.63 – 2.75
+17.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 13.7K | 0.42% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 70.1K | 0.65% |
| 3 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 2.2K | 0.35% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 80.2K | 0.29% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 19.2K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Songyong Lian | Chief Executive Officer & Vice-Chairman | 3M | male |
| Yang Li | Executive Chairman | 588.2K | male |
| Min Zhou | Chief Financial Officer & Joint Company Secretary | — | female |
| Siu Ying Kwok | Joint Company Secretary | — | female |
| Vivian Lu | Investor Relations Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2373.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
